Targeted therapy for pulmonary alveolar proteinosis: the time is now

Abstract excerpt

Pulmonary alveolar proteinosis (PAP) is a rare syndrome with a complex pathogenesis leading, at the end, to accumulation of surfactant phospholipids and lipoproteins in the alveoli, and causing progressive respiratory insufficiency [1]. Alongside the most common autoimmune form, affecting more than 90% of patients and characterised by the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF)...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Congenital Diaphragmatic Hernia Studies
• Share to Neonatal Respiratory Health Research
• Share to Respiratory viral infections research